3.9.7. Selisistat

Selisistat is a selective SirT1 inhibitor which removes acetyl groups on proteins, including mHTT. Therefore, blocking the deacetylation of mHTT should activate clearance. In early-stage HD patients, selisistat improved TMS, but not in most measures of cognition, mood, and functionality [146,147].

#### 3.9.8. Tauroursodeoxycholic Acid/Ursodiol

Tauroursodeoxycholic acid (TUDCA) is a bile acid and has antiapoptotic properties in a mouse model of HD. Mice given TUDCA showed less striatal atrophy, apoptosis, and reduced locomotor and sensory-motor defects [148]. A commercially available uroursodeoxycholic acid precursor, ursodiol, has been examined in a phase I trial, but to date, not reported.
